Article Text

Download PDFPDF

O-031 Comparison Of Bnp And Nt-pro-bnp For Assessment Of The Patent Ductus Arteriosus In Very Preterm Infants
  1. K König1,
  2. KJ Guy2,
  3. G Walsh2,
  4. SM Drew2,
  5. CP Barfield2
  1. 1Neonatal and Paediatric Intensive Care Unit, Children’s Hospital Lucerne, Lucerne, Switzerland
  2. 2Department of Paediatrics, Mercy Hospital for Women, Melbourne, Australia


Background and aims B-type natriuretic peptide (BNP) and N-terminal-pro-BNP (NTproBNP) have been shown to correlate with the size of patent ductus arteriosus (PDA) in preterm infants. We investigated whether BNP or NTproBNP is more accurate for assessment of a PDA.

Methods Prospective observational study. Preterm infants born.

Results 60 infants were recruited, 58 had complete datasets. The cohort’s mean (SD) gestational age was 273 (22) weeks and had a mean (SD) birth weight of 1032 (315) grams. 46 (79.3%) infants had a PDA with a mean (SD) PDA diameter of 3.2 (0.9) mm. Median (IQR) BNP levels: 486.5 (219–1316) pg/ml for infants with PDA, 190 (95.5–514.5) pg/ml for infants without PDA. Median (IQR) NTproBNP levels: 10858.5 (6319–42108) pg/ml for infants with PDA, and 7488 (3363–14227.5) pg/ml for infants without PDA. Both BNP and NTproBNP showed a significant correlation with PDA size in this cohort: BNP R=0.35 (p = 0.0066); NTproBNP R = 0.31 (p = 0.018).

Conclusion BNP and NTproBNP were closely correlated to PDA size. Both markers were useful for assessment of PDA size in this cohort of very preterm infants.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.